Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.

Geoffrey Duyk M.D., Ph.D

Geoffrey Duyk M.D., Ph.D

2012

Dr. Duyk is founder and Managing Partner of Circularis LP, a group focused on supporting technology enabled companies that advance the circular economy and promote sustainability as well as resource efficiency. Prior to Circularis Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies/TPG Biotechnology from 2004 to 2017.  Prior to TPG Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center.

Dr. Duyk holds a PhD and MD from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI.

Dr. Duyk currently serves on the Board of Directors of Elevance Renewable Sciences, Regen Holdings and Inocucor.

Dr. Duyk is a member of the BOD and the executive committee for the American Society of Human Genetics. In addition he is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the Executive committee. He is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the R&D committee. He has also served as a member of the SAB for Bayer Crop Sciences.